Drug Interactions between indacaterol and Uritact DS
This report displays the potential drug interactions for the following 2 drugs:
- indacaterol
- Uritact DS (hyoscyamine/methenamine/methylene blue/phenyl salicylate)
Interactions between your drugs
methylene blue indacaterol
Applies to: Uritact DS (hyoscyamine / methenamine / methylene blue / phenyl salicylate) and indacaterol
MONITOR: Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.
MANAGEMENT: Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.
References
- Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981): 402-4
- "Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985): 443-9
- "Product Information. Proventil (albuterol)." Schering Corporation PROD (2002):
- "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals PROD (2001):
- "Product Information. Isuprel (isoproterenol)." Sanofi Winthrop Pharmaceuticals PROD (2001):
- "Product Information. Serevent (salmeterol)." Glaxo Wellcome PROD
- "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals PROD (2001):
- Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5
- Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31
- "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim PROD (2001):
- "Product Information. Tornalate (bitolterol)." Apothecon Inc (2022):
- "Product Information. Xopenex (levalbuterol)." Sepracor Inc PROD (2001):
- "Product Information. Foradil (formoterol)." Novartis Pharmaceuticals PROD (2001):
- "Product Information. Brovana (arformoterol)." Sepracor Inc (2006):
- "Product Information. S2 Inhalant (racepinephrine)." Nephron Pharmaceuticals (2010):
- "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals (2011):
- "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline (2013):
- "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim (2014):
Drug and food interactions
hyoscyamine food
Applies to: Uritact DS (hyoscyamine / methenamine / methylene blue / phenyl salicylate)
GENERALLY AVOID: Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system. No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load. However, one study found impairment of attention in subjects given atropine 0.5 mg or glycopyrrolate 1 mg in combination with alcohol.
MANAGEMENT: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.
References
- Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.